Dermatological Considerations for Transgender and Gender Diverse Patients: An Australian Perspective

This study examined the current prescribing patterns of Australian dermatologists in treating androgenetic alopecia in men, highlighting the limited treatment options available despite the condition's prevalence and psychological impact.

This systematic review reported that gender-affirming hormone therapy may lead to changes in hair growth patterns, with differing effects for transgender men and women, potentially impacting quality of life.

This study found that transgender and gender diverse patients on masculinizing hormone therapy had 2.5 times the rate of androgenetic alopecia compared to cisgender women.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This review discusses treatment options for androgenetic alopecia in transgender and gender-diverse patients, highlighting first-line treatments like topical minoxidil and finasteride, but reports no new clinical results.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses skin diseases in transgender patients receiving gender-affirming hormone therapy and procedures, highlighting unique conditions and the underdiagnosis that affects their quality of life and mental health.

This article reviews the unique health issues and preventive care recommendations for LGBT individuals, emphasizing dermatologic considerations and the importance of culturally competent care, but reports no new clinical findings.

This review discusses the dermatologic needs and care considerations for transgender patients undergoing gender transition, highlighting the unique role dermatologists can play, but it does not report new clinical results.

This article addresses the complexity of treating acne in female-to-male transgender adolescents undergoing testosterone therapy, highlighting concerns about co-administered treatments and their potential risks.

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This review examines hair removal practices prior to genital gender affirming surgery, noting current variations and offering a practical laser hair removal approach, but reports no new clinical results.

In this study, cross-sex hormone therapy affected hair growth patterns differently, with estrogen reducing hair growth in male-to-female transsexuals and testosterone increasing it in female-to-male transsexuals; however, male typical hair diameters were not fully reached in the latter group after 12 months.